Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 506

Sort by

Sort Order Select

Journal Articles

Clinical Outcomes of Patients with AML Receiving Lower Intensity Chemotherapy with or without the Use of Granulocyte-Colony Stimulating Factor (GCSF)

Hannah Goulart, Alexandre Bazinet, Caitlin R Rausch, Koji Sasaki, Courtney D. DiNardo, Naval Daver, Alex Bataller, Naveen Pemmaraju, Nicholas J. Short, Jayastu Senapati, Ghayas C. Issa, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 5968.

https://doi.org/10.1182/blood-2024-202643

Published: 2024

Journal Articles

A First in Human Study of VOB560 in Combination with MIK665 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, or Multiple Myeloma

Blood (2024) 144 (Supplement 1): 5997.

https://doi.org/10.1182/blood-2024-199074

Published: 2024

Journal Articles

Phase 1 Study of AXL/MER/CSF1R Inhibitor Q702 with Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Abhishek Maiti, Sean M. Post, Courtney D. DiNardo, Naval Daver, Tapan M. Kadia, Allison Pike, Hyunsoo Hwang, Xuelin Huang, Michael Andreeff, Farhad Ravandi, Jinho CHOI, Hyunji Ahn, Jeongjun Kim, Kiyean Nam, Gautam Borthakur

Blood (2024) 144 (Supplement 1): 5994.

https://doi.org/10.1182/blood-2024-202834

Published: 2024

Journal Articles

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 (Lacutoclax) As Monotherapy and in Combination with Azacitidine in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Juan Miguel Bergua Burgues, Kristin Koenig, Pau Montesinos, Dale L. Bixby, Patrick W. Burke, Naval Daver, Stephen P. Anthony, Fenlai Tan, Yi Chen, Yu Chen, Ignacio Casas Aviles, Emily K Curran

Blood (2024) 144 (Supplement 1): 6009.

https://doi.org/10.1182/blood-2024-208792

Published: 2024

Journal Articles

Efficacy of Combinations of Targeted Agents Against Dependencies in Mecom Rearranged AML Identified By Unbiased Chemical and CRISPR Screens

Christine Birdwell, Warren C. Fiskus, Christopher Peter Mill, Surbhi Sharma, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Koji Sasaki, John A. Davis, Kaberi Das, Hanxi Hou, Michele Ceribelli, Kapil N. Bhalla

Blood (2024) 144 (Supplement 1): 5739.

https://doi.org/10.1182/blood-2024-206206

Published: 2024

Journal Articles

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2024-206801

Published: 2024

Journal Articles

Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy

Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Sa A. Wang, Wei Wang, Sanam Loghavi, Naval Daver, Courtney D. DiNardo, Ghayas C. Issa, Hussein A. Abbas, Cedric Nasnas, Alex Bataller, Samuel Urrutia, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short

Blood (2024) 144 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2024-212036

Published: 2024

Journal Articles

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Jennifer Marvin-Peek, Hagop M. Kantarjian, Wei-Ying Jen, Gautam Borthakur, Naval Daver, Abhishek Maiti, Nicholas J. Short, Steven M. Kornblau, Naveen Pemmaraju, Eitan Kugler, Alexandre Bazinet, Yesid Alvarado-Valero, Hussein A. Abbas, Guillermo Garcia-Manero, Uday Popat, Elizabeth J. Shpall, Farhad Ravandi, Courtney D. DiNardo, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 3572.

https://doi.org/10.1182/blood-2024-202414

Published: 2024

Journal Articles

Survival Benefits of Complete Cytogenetic Response in Patients with Newly Diagnosed Myelodysplastic Syndrome

Roberta Santos Azevedo, Hagop M. Kantarjian, Elias Jabbour, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle Hammond, Samuel Urrutia, Carlos E. Bueso-Ramos, Keyur P. Patel, Guillermo Montalban-Bravo, Nicholas J. Short, Naval Daver, Gautam Borthakur, Tapan M. Kadia, William G. Wierda, Guillermo Garcia-Manero, Koji Sasaki

Blood (2024) 144 (Supplement 1): 6727.

https://doi.org/10.1182/blood-2024-201864

Published: 2024

Journal Articles

Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation

Courtney D. DiNardo, Kelly S. Chien, Jillian Mullin, Danielle Hammond, Jeremy Ramdial, Tapan M. Kadia, Fadi G. Haddad, Musa Yilmaz, Koji Sasaki, Ghayas C. Issa, Koichi Takahashi, Elizabeth J. Shpall, Farhad Ravandi, Naval Daver, Hagop Kantarjian

Blood (2024) 144 (Supplement 1): 1527.2.

https://doi.org/10.1182/blood-2024-208771

Published: 2024

Journal Articles

A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Trial in Progress

Nicholas J. Short, Farhad Ravandi, Naval Daver, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Musa Yilmaz, Ghayas C. Issa, Regina Abramova, Araceli Isabella Garza, Hagop M. Kantarjian, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 4288.1.

https://doi.org/10.1182/blood-2024-200923

Published: 2024

Journal Articles

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Blood (2024) 144 (Supplement 1): 6126.

https://doi.org/10.1182/blood-2024-207413

Published: 2024

Journal Articles

Outcomes of Patients with IDH1 -Mutated Myeloid Neoplasms Treated with Olutasidenib

Kelly S. Chien, Koji Sasaki, Deborah McCue, Naval Daver, Tapan M. Kadia, Nicholas J. Short, Ghayas C. Issa, Guillermo Montalban-Bravo, Fadi G. Haddad, Danielle Hammond, Mahesh Swaminathan, Alexandre Bazinet, Farhad Ravandi, Guillermo Garcia-Manero, Sherry Pierce, Hagop M. Kantarjian, Courtney D. DiNardo

Blood (2024) 144 (Supplement 1): 6042.

https://doi.org/10.1182/blood-2024-208611

Published: 2024

Journal Articles

A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 1047.

https://doi.org/10.1182/blood-2024-211343

Published: 2024

Journal Articles

ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis

Blood (2024) 144 (Supplement 1): 805.

https://doi.org/10.1182/blood-2024-204230

Published: 2024

Journal Articles

Enhancing Macrophage Mediated Phagocytosis in AML: The Complementary Mechanisms of Venetoclax and Azacitidine Combination Therapy

Zhe WANG, Xufeng Chen, Simone Sidoli, Anna Skwarska, Yannan Jia, Lei Yang, Varun Gupta, Shikhar Sharma, Iannis Aifantis, Hussein A. Abbas, Naval Daver, Qi Zhang Tatarata, Marina Konopleva

Blood (2024) 144 (Supplement 1): 207.

https://doi.org/10.1182/blood-2024-198057

Published: 2024

Journal Articles

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 4601.

https://doi.org/10.1182/blood-2024-204040

Published: 2024

Journal Articles

Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3 -Tyrosine Kinase Domain (TKD) Mutations

Blood (2024) 144 (Supplement 1): 841.

https://doi.org/10.1182/blood-2024-204042

Published: 2024

Journal Articles

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Blood (2024) 144 (Supplement 1): 213.

https://doi.org/10.1182/blood-2024-194827

Published: 2024

Journal Articles

Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

Pau Montesinos, Montserrat Arnan, Stephane De Botton, Maria Calbacho, Rebeca Rodriguez Veiga, Pierre Bories, Belén Ansoleaga, Thomas Hueso, Naval Daver, Lydia Wunderle, Andreas Harstrick, Kerstin Pietzko, Pallavi Hajela, Alexandra Vasile, Tania Witte, Elmarie Saenger, Christian Récher

Blood (2024) 144 (Supplement 1): 738.

https://doi.org/10.1182/blood-2024-194356

Published: 2024

NARROW

Clinical Outcomes of Patients with AML Receiving Lower Intensity Chemotherapy with or without the Use of Granulocyte-Colony Stimulating Factor (GCSF)

A First in Human Study of VOB560 in Combination with MIK665 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, or Multiple Myeloma

Phase 1 Study of AXL/MER/CSF1R Inhibitor Q702 with Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Efficacy of Combinations of Targeted Agents Against Dependencies in Mecom Rearranged AML Identified By Unbiased Chemical and CRISPR Screens

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Survival Benefits of Complete Cytogenetic Response in Patients with Newly Diagnosed Myelodysplastic Syndrome

Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation

A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Trial in Progress

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Outcomes of Patients with IDH1 -Mutated Myeloid Neoplasms Treated with Olutasidenib

A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis

Enhancing Macrophage Mediated Phagocytosis in AML: The Complementary Mechanisms of Venetoclax and Azacitidine Combination Therapy

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3 -Tyrosine Kinase Domain (TKD) Mutations

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only